يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
شركة CytomX Therapeutics تقدم بيانات ما قبل السريرية لعقار Interferon Alpha-2b المنشط مشروطًا في الاجتماع السنوي SITC 2023
CytomX Therapeutics, Inc. +0.59% Pre
CytomX Therapeutics, Inc. CTMX | 3.42 3.52 | +0.59% +2.92% Pre |
- IND filing for CX-801 anticipated by the end of 2023 -
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California.
Details for the poster presentation are as follows:
Presentation Title: Conditionally activated IFNa induces an inflammatory tumor microenvironment in preclinical models and increases efficacy in combination with checkpoint blockade
Abstract Number: 1064
Poster Hall A
Session Date and Time: November 4, 2023, 9:00 am - 8:30 pm PT
